One type of immunotherapy aims to improve the immune response against cancer cells by blocking programmed cell death protein 1 (PD-1), a protein that induces inhibition of the immune system during the formation of the PD-1/PD-L1 pathway by targeting PLD1 (programmed cell death ligand1), which is involved in tumor cell growth and survival. Here, CD274 is linked to cancer.